![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
January 30, 2026
10 cancer research discoveries in 2025 by ECOG-ACRIN and PrECOG that captured attention across the scientific and patient advocacy communities
January 30, 2026
This phase 3 study compares BRAF-targeted therapy (dabrafenib-trametinib) to TKI therapy (cabozantinib) in patients with disease progression after standard treatments
January 30, 2026
The latest research in breast cancer, geriatric oncology, leukemia, NCI-MATCH, and symptom management
January 30, 2026
Timely updates on research leaders, presentations at medical meetings and more
December 19, 2025
This companion study aims to build a biobank of tumor tissue samples to identify factors driving breast cancer recurrence despite treatment
December 19, 2025
Timely updates on research leaders, presentations at medical meetings and more
November 21, 2025
A recap of the Fall 2025 Group Meeting, trial results from ESMO, and a look ahead to the ASH Annual Meeting and Exposition and the San Antonio Breast Cancer Symposium
November 21, 2025
Several themes emerged as key areas of focus for ECOG-ACRIN during the Fall 2025 Group Meeting
November 21, 2025
In an annual evaluation, 37 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
November 21, 2025
Compliance guidance for an updated policy that aims to accelerate free public access to research funded by the National Institutes of Health
November 21, 2025
This clinical trial is exploring whether PARP inhibitors will improve outcomes for patients with early-stage pancreas cancer that has BRCA or PALB2 mutations
October 17, 2025
A welcome to the new National Cancer Institute director, an update on the federal budget and its implications, and a look ahead to next week's Group Meeting